Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Gleptomet vs Janumet in Healthy Adults
NCT05798715Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of gleptoferron + toltrazuril in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Nov 2022; status: completed.
02
Drugs
gleptoferron + toltrazuril
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05798715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798715.